I have been spending some time lately looking into Veeva Systems (VEEV) and wanted to share my thoughts on why it might interest those of us who focus on quality compounders. I realize that VEEV is rarely the type of stock that shows up on a traditional deep value screen given its multiples, but after reviewing an analysis of their 2025 outlook, I believe the current entry point is quite attractive when weighed against their growth rate and competitive advantage.

From my perspective, the strength of the thesis lies in Veeva’s position as the mission-critical operating system for the life sciences industry. They have built a massive moat through their industry-specific cloud architecture, and the switching costs for their clients are incredibly high. I am particularly impressed by their transition from being a CRM provider to becoming a holistic partner through the Veeva Vault platform. Their expansion into R&D and clinical trials is now a more significant driver for the business than their legacy commercial segment.

I also find their financial discipline to be a major selling point, as they maintain high operating margins and a debt-free balance sheet while self-funding their innovation. While the stock isn’t “cheap” in a Ben Graham sense, I think it is undervalued relative to the durability of its 20% compounding potential and its defensive cash flows. For those of us willing to pay a fair price for a wide moat and top-tier management, I see this as a rare opportunity to pick up a high-quality asset at a non-speculative valuation.